Nevertheless, IL23A, SPARCL1, and PDGFB may be key mediators driving pathological inflammation and fibrosis in trachoma, and molecules that inhibit their action could hold therapeutic potential in preventing scarring progression. The gene discussed is SPARCL1; the disease is inclusion conjunctivitis.